drugset / Trial / NCT04711811

Individual Patient Expanded Access IND of HB-adMSCs for Chronic Musculoskeletal Pain.

NCT04711811 ↗

Expanded access No longer available Hope Biosciences Research Foundation

Summary

This is an Individual Patient Expanded Access IND providing multiple administrations of HBadMSCs for the treatment of Chronic Musculoskeletal Pain. The study duration is approximately 32 weeks, during that time the study subject will complete 1 screening visit, 6 infusion visits, one follow-up visit without infusion and one end of study visit. Next day telephone follow-up visits will occur following each infusion. Efficacy and safety labs as well as quality of life and VAS scores will be obtained.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject HB-adMSC Cell therapy 200 cells Intravenous

Indications